drugset / Trial / NCT02435927
ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin
Phase 1
Unknown
60 enrolled
National Cancer Centre, Singapore
ASLAN Pharmaceuticals · collabNational Medical Research Council (NMRC), Singapore · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase I, open-label, dose escalation study of ASLAN001 given in combination with CAPOX or mFolfox6, in patients with metastatic solid tumours, whom are suitable to receive CAPOX or mFolfox6, or with tumours that have dysregulated EGFR or HER2 signaling.
Timeline
- Start
- 2014-08
- Primary completion
- 2021-06
- Completion
- 2021-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Varlitinib | Small molecule | — | — |
| Background | Capecitabine | Small molecule | 850 mg/m2 | Oral |
| Background | Leucovorin | Small molecule | 400 unknown | Intravenous |
| Background | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |
| Background | Oxaliplatin | Small molecule | 130 mg/m2 | Intravenous |
| Background | fluorouracil | Small molecule | 400 mg/m2 | Intravenous |
| Background | fluorouracil | Small molecule | 2400 mg/m2 | Intravenous |